![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » UK Fines Four Pharma Companies in Antidepressant Scheme
UK Fines Four Pharma Companies in Antidepressant Scheme
March 13, 2020
The UK’s Competition and Markets Authority (CMA) fined four pharma companies more than $4 million for conspiring to share the market and fix prices for the antidepressant drug nortriptyline.
The CMA found King Pharmaceuticals and Auden Mckenzie entered an anti-competitive arrangement to share the market by supplying nortriptyline to a large pharmaceutical wholesaler. The authority fined Accord-UK $2.45 million because the company took control of Auden Mckenzie’s nortriptyline business after the market sharing ended.
Accord-UK and Auden Mckenzie also agreed to pay $1.3 million to the National Health Service in connection with the case.
The authority also fined Lexon UK $1.6 million for sharing information on pricing and volumes with King Pharmaceuticals and Alissa Healthcare Research. King and Alissa received smaller fines.
Upcoming Events
-
21Oct